Every tumor is different
with its own ever-changing unique genomic profile

We target the source
developing new potential targeted therapies for cancer patients
with an activated Notch pathway

About us
Ayala pharma

We target cancer at its source

Dysregulation of the Notch pathway may lead to carcinogenic activity. Our investigational new drug, AL101, was developed to inhibit the Notch pathway in cancer.

Learn more
Ayala pharma

We target uniqueness

As precision oncology and diagnostics evolve, we can start to target the underlying mechanisms for cancers, especially for rare cancers where no approved therapies exist.

Clinical trial

The right match

By matching the right patient to the right drug, we hope to achieve the promise of precision oncology: deliver better clinical responses and greater benefits for patients.

Learn more

Be informed